The FDA has approved Lilly’s Lyumjev rapid-acting mealtime insulin to reduce high blood sugar after meals and keep blood glucose levels in-range. This approval offers another important mealtime insulin option for adults with Type 1 or Type 2 diabetes and was approved in Japan and Europe in March 2020.
Lyumjev can be taken at the beginning of a meal (strongly recommended) or 20 minutes after starting it. This flexibility is due to the faster onset and offset of the insulin.
